A Study to Observe Treatment Patterns and Outcomes in Participants in Saudi Arabia With Human Epidermal Growth Factor Receptor 2 (HER2-Positive) Unresectable Locally Advanced or Metastatic Breast Cancer (LA/mBC)
This is a prospective, national, multicenter, non-interventional study designed to enroll participants who have an initial diagnosis of unresectable LA/mBC made up to 6 months prior to registry enrollment. These participants will be prospectively followed for at least 5 years after study enrollment to evaluate their anti-cancer treatments. Data on participants' previous anti-cancer treatments for breast cancer will be collected retrospectively at study entry.
Metastatic Breast Cancer
OTHER: No intervention
Progression-Free Survival (PFS), Up to 5 years
Number of Participants With Adverse Events, Up to 5 years|Overall Survival (OS), Up to 5 years|Objective Response Rate (ORR) Per Anti-Cancer Treatment Regimen, Up to 5 years|Duration of Response (DoR) Per Anti-Cancer Treatment Regimen, Up to 5 years|Quality of Life, as Assessed by the EuroQol 5-Dimensions Questionnaire (EQ-5D), Up to 5 years|Overall Health Status, as Assessed by the Functional Assessment of Cancer Therapy-Breast (FACT-B), Up to 5 years
This is a prospective, national, multicenter, non-interventional study designed to enroll participants who have an initial diagnosis of unresectable LA/mBC made up to 6 months prior to registry enrollment. These participants will be prospectively followed for at least 5 years after study enrollment to evaluate their anti-cancer treatments. Data on participants' previous anti-cancer treatments for breast cancer will be collected retrospectively at study entry.